Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

129 results about "Phosphoprotein phosphatase" patented technology

A protein phosphatase is a phosphatase enzyme that removes a phosphate group from the phosphorylated amino acid residue of its substrate protein. Protein phosphorylation is one of the most common forms of reversible protein posttranslational modification (PTM), with up to 30% of all proteins being phosphorylated at any given time. Protein kinases (PKs) are the effectors of phosphorylation and catalyse the transfer of a γ-phosphate from ATP to specific amino acids on proteins. Several hundred PKs exist in mammals and are classified into distinct super-families. Proteins are phosphorylated predominantly on Ser, Thr and Tyr residues, which account for 79.3, 16.9 and 3.8% respectively of the phosphoproteome, at least in mammals. In contrast, protein phosphatases (PPs) are the primary effectors of dephosphorylation and can be grouped into three main classes based on sequence, structure and catalytic function. The largest class of PPs is the phosphoprotein phosphatase (PPP) family comprising PP1, PP2A, PP2B, PP4, PP5, PP6 and PP7, and the protein phosphatase Mg²⁺- or Mn²⁺-dependent (PPM) family, composed primarily of PP2C. The protein Tyr phosphatase (PTP) super-family forms the second group, and the aspartate-based protein phosphatases the third. The protein pseudophosphatases form part of the larger phosphatase family, and in most cases are thought to be catalytically inert, instead functioning as phosphate-binding proteins, integrators of signalling or subcellular traps. Examples of membrane-spanning protein phosphatases containing both active (phosphatase) and inactive (pseudophosphatase) domains linked in tandem are known, conceptually similar to the kinase and pseudokinase domain polypeptide structure of the JAK pseudokinases. A complete comparative analysis of human phosphatases and pseudophosphatases has been completed by Manning and colleagues, forming a companion piece to the ground-breaking analysis of the human kinome, which encodes the complete set of ~536 human protein kinases.

Compositions and methods for enhancing cognitive function

ActiveUS20080213406A1Prevent tau hyperphosphorylationOrganic active ingredientsBiocideTraditional medicineGeneral health
Disclosed are compositions for promoting general health and well-being, comprising an extract of a botanical raw material, wherein said extract inhibits the carboxyl demethylating activity of a protein phosphatase, and methods of making and using same.
Owner:SIGNUM BIOSCIENCES INC +1

Protein kinase and phosphatase inhibitors and methods for designing them

The present invention provides a method for identifying inhibitors of protein kinases and / or protein phosphatases. Methods are also provided for inhibiting protein kinase and / or protein phosphatase activity. Specific non-peptide protein tyrosine kinase and / or protein phosphatase inhibitors are provided. The protein kinase or protein phosphatase inhibitors of the present invention may be used to treat a number of conditions in patients, including cancer, psoriasis, arthrosclerosis, immune system activity, Type II diabetes, and obesity.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK

Anhydride modified cantharidin analogues useful in the treatment of cancer

Anhydride modified cantharidin analogues useful in the treatment of certain forms of cancer also methods for the screening for anti-cancer activity of these analogues and / or their ability to sensitise cancer cells to cancer treatment. The modified cantharidin analogues have structure (I) or (II), wherein R1, R2, R3 and R4 are H, aryl or alkyl; X is O, N or S; Y is O, S, NH, NR; R is alkyl or aryl; A and B are H or CH3; W and Z are CHOH or C═O. These compounds inhibit protein phosphatase.
Owner:MCCLUSKEY ADAM +3

Bindwood sapogenin and its preparation method and use

The invention relates to a hederagenin and a preparation method and purposes thereof. The compound is that the hederagenin is distilled from Nigella glandulifera freyn by degreasing, leaching and macroporous resin absorption, a structure of the hederagenin is confirmed by using physico-chemical constants, spectra database and single crystal method of X-ray diffractometry, the distilled hederagenin is proved in vitro to have the effect of tyrosine protein phosphatase PTP1B retardant and purposes as anti-diabetes drugs and health care products, meanwhile, the hederagenin is also applicable to be combination of drugs made from the compound or derivatives of the compound.
Owner:XINJIANG TECHN INST OF PHYSICS & CHEM CHINESE ACAD OF SCI

Thiazole derivative

PCT No. PCT / JP97 / 02609 Sec. 371 Date Mar. 24, 1998 Sec. 102(e) Date Mar. 24, 1998 PCT Filed Jul. 29, 1997 PCT Pub. No. WO98 / 04536 PCT Pub. Date Feb. 5, 1998A thiazole compound of the formula: wherein T is lower alkylene; u is 0 or 1; R1 and R2 are the same or different and are each H, or lower alkyl, etc.; R3 is R4 is H or lower alkanoyloxy-lower alkyl, which shows inhibitory activity on protein kinase C (PKC, Ca2+ / phospholipid-depending serine / threonine protein phosphatase), and are useful as a protein kinase C inhibitor.
Owner:OTSUKA PHARM CO LTD

Ruthenium-containing coordination compound and preparation method thereof

The invention relates to a ruthenium-containing coordination compound. The ruthenium-containing coordination compound is a coordination compound expressed by ARu(X'Y')Z or [ARu(XY)Z]+B-, wherein A is arene; XY is one of dialkyl amine, and feiluolin and derivatives thereof; the X'Y' is one of 8-hydroxyguinoline and a derivative thereof; Z is one of halogen, -SCN, -N3,-SCH3, -SH, -COOH, pyridyl, pyridyl substituted by one or more groups in C1-C3 alkyl and tyrosine kinase inhibitor with a single coordination atom; and B- is PF6- or BF4-. The new ruthenium-containing coordination compound can effectively act on DNA, or substitute a high-selectivity protein kinase inhibitor or a derivative thereof for one or more of ligands in the cytotoxicity organic metal ruthenium coordination compound, and can act on the protein kinase (or protein phosphatase) and a multi-target point combining molecular anti-tumor compound of DNA at the same time.
Owner:INST OF CHEM CHINESE ACAD OF SCI

Arabidopsis thaliana AtPP2CA2 gene and application thereof

The invention discloses protein phosphatases 2C of arabidopsis thaliana and encoding gene and application thereof. The invention aims at providing the protein phosphatases 2C of the arabidopsis thaliana, the encoding gene thereof, and application thereof to controlling growth and development and stress resistance of plants. The AtPP2CA2 gene disclosed by the invention is found through screening from a cDNA database of arabidopsis thaliana processed by ABA (Abscisic Acid), salt and drought induction by using a gene chip method, the number of the AtPP2CA2 gene in GenBank is At5g59220, the length of cDNA of the gene is 1242bp, and the gene encodes 413 aa proteins. The gene disclosed by the invention and the encoding protein thereof have great theoretic and practical significance in research of inverse resistance mechanism of plants and improvement of inverse resistance such as drought endurance, salt tolerance and the like and relevant properties, and play an important role in the improvement of inverse-resistance gene engineering of plants, and have broad application prospect.
Owner:HUNAN UNIV

Human dosing of phosphatase inhibitor

InactiveUS20160074390A1Inhibit protein phosphatase 2A (PP2A)Heavy metal active ingredientsBiocidePhosphatase inhibitorBiochemistry
The present invention provides a method of inhibiting protein phosphatase 2A (PP2A) in a human subject in need thereof comprising administering to the subject an amount of from 0.1 mg / m2 to 5 mg / m2 of a compound having the structureor a salt, zwitterion, or ester thereof, so as to thereby inhibit protein phosphatase 2A (PP2A) in the subject.
Owner:LIXTE BIOTECH

Gene for increasing the production of plant biomass and/or seeds and method for use thereof

A technique by which the production of plant biomass can be significantly increased is provided. A protein phosphatase 2C gene having 3 consensus sequences comprising the amino acid sequences shown in SEQ ID NOS: 1-3 from the N-terminal side in such order is over-expressed.
Owner:TOYOTA JIDOSHA KK

Methods for treating a variety of diseases and conditions, and compounds useful therefor

In accordance with the present invention, there are provided novel compounds that have a variety of properties, i.e., antioxidant, anti-inflammatory, antiviral, antibacterial, and antifungal properties. Invention compounds, therefore, have the ability to impart a variety of beneficial physiological effects, e.g., to protect neurons and / or to promote neuroregeneration and / or to promote memory formation and / or to act as protein phosphatase or kinase inhibitors and / or to act as lipoxygenase inhibitors. Such compounds are useful for treatment of a variety of indications, including neurodegenerative diseases and conditions, diabetes, ischemia associated with heart disease, and memory deficit. In another aspect of the present invention, there are also provided formulations containing one or more of the above-described compounds, optionally further containing additional neurologically active compound(s) and / or adjuvants to facilitate delivery thereof across the blood / brain barrier. In still another aspect of the present invention, there are further provided methods for treating a wide variety of neurological indications, e.g., acute neural injuries, chronic injuries, promoting memory formation, and the like.
Owner:SALK INST FOR BIOLOGICAL STUDIES

Method for increasing the production of plant biomass and/or seeds and method for producing plant capable of producing increased amount of biomass and/or seeds

The production of biomass and / or seeds is further increased. The production of biomass and / or seeds by a plant can be further increased by supplying glutathione to a plant into which a gene encoding protein phosphatase 2C having characteristic consensus sequences has been introduced.
Owner:TOYOTA JIDOSHA KK

Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same

Disclosed herein are rhodanine derivatives, a method for the preparation thereof, and a pharmaceutical composition containing the same. The rhodanine derivatives have inhibitory activity against protein phosphatases (PPase) such as PTP1B, Prl-3, LAR, CD45, Cdc25A, Cdc25B, Cdc25C, Yop, PP1 and VHR, and can be applied for the prevention and treatment of PPase-caused diseases, including autoimmune diseases, diabetes, impaired glucose intolerance, insulin resistance, obesity, cancers, etc. when the inhibitory activity thereof is modulated.
Owner:KOREA RES INST OF BIOSCI & BIOTECH +1

Protein phosphatase inhibitors that cross the blood brain barrier

The present invention provides a method for in vivo delivery of endothal to a target cell in a subject, the method comprising administering to the subject a compound having the structure: Formula (I).
Owner:LIXTE BIOTECH

Identification and application of cotton drought-resistance related gene GhDRP1

InactiveCN106520798AReduce expressionWeakened drought resistanceHydrolasesFermentationAgricultural scienceExon
The invention discloses identification and an application of a cotton drought-resistance related gene GhDRP1. The invention provides the novel gene GhDRP1 from a cotton PP2C protein phosphatase family, and the expression of the gene is induced in the case of cotton drought stress. A gene sequence of the GhDRP1 consists of 3 introns and 4 exons. A gene coding region of the GhDRP1 is 1254bp long, and a protein containing 417 amino acids is encoded. The GhDRP1 protein is located in a cell nucleus. In the case of the cotton drought stress, the gene expression is obviously increased, showing that the gene is a drought inducing gene. Experiments show that the drought resistance of cotton can be weakened through the over-expression of the GhDRP1, and the drought resistance of the cotton can be enhanced by inhibiting the expression of the GhDRP1. In conclusion, the invention provides the functional gene which has an important application value in improving the drought resistance of the cotton.
Owner:HUAZHONG NORMAL UNIV

Reagents for the detection of protein phosphorylation in Leukemia signaling pathways

The invention discloses nearly 288 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor / Scaffold proteins, Cytoskeletal proteins, Cellular Metabolism enzymes, G Protein / GTPase Activating / Guanine Nucleotide Exchange Factor proteins, Immunoglobulin Superfamily proteins, Inhibitor proteins, Lipid Kinases, Nuclear DNA Repair / RNA Binding / Transcription proteins, Serine / Threonine Protein Kinases, Tyrosine Kinases, Protein Phosphatases, and Translation / Transporter proteins.
Owner:CELL SIGNALING TECHNOLOGY

Protein kinase and phosphatase substrates and multiplex assays for identifying their activities

The present invention provides protein kinase and protein phosphatase substrates, methods of detecting protein kinases and protein phosphatases, and kits for detection of protein kinases and protein phosphatases. The substrates, methods, and kits use multiple substrates that can easily be differentiated from all other substrates, thus enabling rapid and easy detection of protein kinase or protein phosphatase activities. The invention also provides methods of directionally cloning nucleic acids.
Owner:STATAGENE CALIFORNIA

Rice stress resistance related gene OsPP2C44 and coded protein and application thereof

InactiveCN102943084AImprove resistance to osmotic stressResponsive to stressHydrolasesFermentationBiotechnologyAbscisic acid
The invention discloses an OcPP2C44 gene separated and cloned from rice deoxyribonucleic acid (DNA) fragments and related to rice stress resistance. The protein of the genetic code contains protein phosphatase family conservative catalytic structural domain and is a member of a PP2C type of the gene family. The OsPP2C44 gene is performed with inducible expression of high salinity, low temperature, high temperature and abscisic acid (ABA), and overexpression OsPP2C44 can improve osmotic stress resistance capability of rice during seedling stage and is related to rice stress resistance. The rice gene of the OcPP2C44 gene has obvious response to adverse situation, can be applied to plant stress resistance breeding, and improves stress resistance of plants.
Owner:SHANGHAI AGROBIOLOGICAL GENE CENT

Protein kinase and phosphatase inhibitors and methods for designing them

InactiveUS20060030544A1Inhibits protein kinase activityInhibits protein phosphatase activityBiocideMetabolism disorderProtein-Tyrosine KinasesProtein kinase domain
The present invention provides a method for identifying inhibitors of protein kinases and / or protein phosphatases. Methods are also provided for inhibiting protein kinase and / or protein phosphatase activity. Specific non-peptide protein tyrosine kinase and / or protein phosphatase inhibitors are provided. The protein kinase or protein phosphatase inhibitors of the present invention may be used to treat a number of conditions in patients, including cancer, psoriasis, arthrosclerosis, immune system activity, Type II diabetes, and obesity.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK

Inhibitors of Protein Phosphatase 1, GADD34 and Protein Phosphatase 1/GADD34 Complex, Preparation and Uses Thereof

InactiveUS20100016235A1Low immunogenicityStimulate immunogenicOrganic active ingredientsBiocideProtein phosphatase 1Depressant
The present invention relates to the use of a protein phosphatase inhibitor selected from an inhibitor of the catalytic subunit of the protein phosphatase 1 (PP1), an inhibitor of GADD34 and an inhibitor of the PP1 / GADD34 complex to prepare a pharmaceutical composition to prevent or treat a cancer in a mammal, wherein the pharmaceutical composition is intended for administration in combination with a product used in a treatment of a cancer.
Owner:INSTITUT GUSTAVE ROUSSY +1

Preparation of a peptide compound (SYRAPRO-2000) and its use for the activation of protein phosphatase-2A1 enzyme

This invention relates to the preparation of a peptide compound (SYRAPRO-2000), its use to activate protein phosphatase-2A enzymes for the dephosphorylation of proteins in vitro and in the cell and its use for inhibiting cell proliferation and induction of death of brain cancer cells and other cancer cells and therefore the treatment of proliferative disorder such as brain cancer and other forms of cancer. Drugs that target the enzymes of the protein phosphorylation / dephosphorylation apparatus of the cell are mostly inhibitor compounds. The present invention describes for the first time the use of an activating compound of a protein phosphatase to modulate the activity of a cell. In this invention, the peptide compound activator of protein phosphatase-2A1 (SYRAPRO-2000) is used to activate protein phosphatase-2A1, thereby causing inhibition of cell proliferation and induction of cell death of transformed T cells and brain cancer cells.
Owner:LIM TUNG HIN YOUNG

Gene for increasing the production of plant biomass and/or seeds and method for use thereof

A technique by which the production of plant biomass can be significantly increased is provided. A gene encoding protein phosphatase 2C having 3 consensus sequences comprising the amino acid sequences shown in SEQ ID NOS: 1-3 from the N-terminal side in such order and a gene encoding glutathione-binding plastid-type fructose 1,6-bisphosphate aldolase is introduced, or an expression control region of endogenous genes corresponding to the genes are modified.
Owner:TOYOTA JIDOSHA KK +1

Application of cucurbitacine B to preparation of cancerous inhibitor of protein phosphatase 2A

The invention belongs to the technical field of medicine, and particularly relates to an application of tetracyclic-triterpene-like compound-like cucurbitacine B separated and extracted from cucurbitaceous plants as a cancerous inhibitor of protein phosphatase 2A. Cucurbitacine B is taken as a main component in the cancerous inhibitor of protein phosphatase 2A, so that the expression of the cancerous inhibitor of protein phosphatase 2A can be inhibited remarkably. The cucurbitacine B can be applied to independent administration or combined treatment, including combined applications with radiotherapy, chemotherapy, surgical treatment, other growth factor inhibitors and sexual hormone inhibitors, any tumor treatment medicament and method.
Owner:HUBEI UNIVERSITY OF MEDICINE

Agents and a method of chromosome preparation using protein phosphatase inhibitors induced premature chromosome condensation (PCC) technique

Agents and a method for generating chromosomes by premature chromosome condensation (PCC) technique utilizes inhibitors of serine / threonine protein phosphatases. When the cells were treated with these agents, they underwent PCC at any phase of cell cycle within 2 hours. This method enables to obtain not only chromosome of mitotic cells but also those from interphase nuclei much easily, quickly and effectively.
Owner:GOTOH EISUKE

Methods and compositions for treatment and diagnosis of alzheimer disease and other disorders

InactiveUS20030165575A1Increasing activity of phosphataseBiocideNervous disorderNeurofibrillary tanglePhosphorylation
The present invention is directed to methods for treating Alzheimer disease and other disorders associated with the presence of neurofibrillary tangles (NFTs) by increasing the activity of a phosphatase towards abnormal hyperphosphorylated tau ("AD P-tau") present in the NFTs of paired helical filaments in the neurons of patients having Alzheimer disease or other NFT-associated disorder. Pharmaceutical compositions and diagnostic methods are also provided. The inventions provide methods of treatment by administering to a subject a therapeutically effective amount of a composition comprising a molecule which increases protein phosphatase activity toward AD P-tau, a phosphatase which dephosphorylates AD P-tau, or a nucleic acid encoding such a phosphatase.
Owner:RES FOUDATION FOR MENTAL HYGIENE INC

Constrained tricyclic sulfonamides

Tricyclic chemical modulators of protein phosphatase 2A are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. The compounds are of the following phenothiazine and dibenzoazepine compounds and similar genera:
Owner:MT SINAI SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products